K-V Files For Ch. 11 As $45M Hologic Bill Comes Due

Law360, New York (August 6, 2012, 5:17 PM EDT) -- Women's health care company K-V Pharmaceutical Co. filed for Chapter 11 protection Saturday in New York, citing its inability to realize full value on its biggest product, preterm-birth drug Makena, and a $45 million milestone payment due on a related rights agreement with Hologic Inc.

The company, which cited $236.6 million in assets and $728.3 million in liabilities, including $420.1 million in long-term debt, said it intends to restructure its financial obligations and continue to operate during its reorganization. Seven K-V subsidiaries also filed for Chapter...
To view the full article, register now.